Drug Database · Clinicians

Iopamidol

Brands (11) Iopamedix, Iopamiro, Scanlux…Show all

US brand (reference label): ISOVUE-M; not a Philippine-registered brand.

Radiographic Contrast Agent (X-Ray Contrast Activity) US FDA class
Water-soluble, nephrotropic, low osmolar x-ray contrast media; Iodinated x-ray contrast media (water-soluble, nephrotropic, low osmolar x-ray contrast media); and others PH FDA category

Rx · Prescription drug20 PH productsPNF-listed
Dispensing: Prescription (Rx) Last updated: Audience: Licensed health professionals
Label text on this page: US FDA-approved label via DailyMed/openFDA, set ID 11e893d2-0183-4581-b908-c8b7302c7edb, version date February 10, 2026 (ISOVUE-M · Bracco Diagnostics Inc). Reproduced verbatim. Philippine-approved indications and doses may differ: check the PH package insert.

Use: Labeled indications

  • Lumbar and thoracic myelography, and computed tomography (CT) myelography in adults and pediatric patients aged 2 years and older Cervical and total columnar myelography and CT myelography in adults CT cisternography in…
US FDA label
Full indications and usage US FDA label

1 INDICATIONS AND USAGE ISOVUE-M is indicated for: Lumbar and thoracic myelography, and computed tomography (CT) myelography in adults and pediatric patients aged 2 years and older Cervical and total columnar myelography and CT myelography in adults CT cisternography in adults Specific concentrations of ISOVUE-M are recommended for each type of imaging procedure [see Dosage and Administration (2.2, 2.3)]. ISOVUE-M is a radiographic contrast agent indicated for: Lumbar and thoracic myelography and computed tomography (CT) myelography in adults and pediatric patients aged 2 years and older Cervical and total columnar myelography in adults CT cisternography in adults (1) Specific concentrations of ISOVUE-M are recommended for each type of imaging procedure.

(2.2, 2.3)

Contraindications

4 CONTRAINDICATIONS None. None (4)

US FDA label

Dosing: Adult

Dosage and administration (US label) US FDA label
  • Individualize the volume and concentration of ISOVUE-M according to the specific dosing tables based on patient age, body weight, and study to be performed. (2.2, 2.3)
  • See full prescribing information for important dosage and administration information. (2.1)
2.1 Important Dosage and Administration Information

2.1 Important Dosage and Administration Information ISOVUE-M is for intrathecal use only. Specific concentrations of ISOVUE-M are recommended for each type of imaging procedure [see Dosage and Administration (2.2, 2.3)]. Individualize the volume, concentration, and injection rate of ISOVUE-M according to the dosing tables [see Dosage and Administration (2.2, 2.3)].

Consider factors such as age, body weight, anticipated pathology and degree and extent of opacification required, structure(s) or area to be examined, concomitant medical conditions, and imaging equipment and technique to be employed. Hydrate patients prior to and following ISOVUE-M administration [see Warnings and Precautions (5.2)].

Use aseptic technique for all handling and administration of ISOVUE-M. ISOVUE-M may be administered at either body temperature (37°C, 98.6°F) or room temperature (20°C to 25°C, 68°F to 77°F). Visually inspect ISOVUE-M for particulate matter and discoloration prior to administration whenever the solution and container permit.

Do not administer ISOVUE-M if particulate matter or discoloration are observed. Do not mix ISOVUE-M with other drugs. ISOVUE-M is packaged in a single-dose vial and intended for one procedure only. Discard any unused portion.

2.2 Recommended Dosage for Intrathecal Procedures in Adults

2.2 Recommended Dosage for Intrathecal Procedures in Adults The recommended doses in adults are shown in Table 1. Administer over 1 minute to 2 minutes. Allow at least 48 hours before repeat administration to avoid overdose; however, whenever possible, 5 days to 7 days is recommended. If CT myelography is performed, delay imaging by at least 4 hours to reduce the degree of contrast.

Table 1: Recommended Concentrations and Volumes of ISOVUE-M for Intrathecal Procedures in Adults Imaging Procedure Concentration (mg Iodine/mL) Volume to Administer Injection Type Lumbar and thoracic myelography 200 10 mL to 15 mL Lumbar Cervical myelography 200 10 mL to 15 mL Lumbar 10 mL Lateral cervical 300 10 mL Lumbar Total columnar myelography 300 10 mL Lumbar CT cisternography 200 4 mL to 6 mL Lumbar

2.3 Recommended Dosage for Intrathecal Procedures in Pediatric Patients Aged 2 Years and Older

2.3 Recommended Dosage for Intrathecal Procedures in Pediatric Patients Aged 2 Years and Older The recommended doses based on age for pediatric patients aged 2 years and older are shown in Table 2. Administer over 1 minute to 2 minutes. Allow at least 48 hours before repeat administration to avoid overdose; however, whenever possible, 5 days to 7 days is recommended.

If CT myelography is performed, delay imaging by at least 4 hours to reduce the degree of contrast. Table 2: Recommended Concentrations and Volumes of ISOVUE-M Based on Age for Intrathecal Procedures in Pediatric Patients Aged 2 Years and Older Imaging Procedure Age Concentration (mg Iodine/mL) Volume to Administer Injection Type Lumbar and thoracic myelography 2 years to 7 years 200 7 mL to 9 mL Lumbar 8 years to 12 years 8 mL to 11 mL Lumbar 13 years and older 10 mL to 12 mL Lumbar

Dosing: Altered kidney function

From the US FDA label · Renal impairment (use in specific populations)

8.6 Renal Impairment The clearance of iopamidol decreases with increasing degree of renal impairment. In addition, preexisting renal impairment increases the risk for acute kidney injury [see Warnings and Precautions (5.2)].

Kidney-specific guidance from renalcarematters.com: in preparation.

Administration

2.1 Important Dosage and Administration Information ISOVUE-M is for intrathecal use only. Specific concentrations of ISOVUE-M are recommended for each type of imaging procedure [see Dosage and Administration ( 2.2 , 2.3 )]. Individualize the volume, concentration, and injection rate of ISOVUE-M according to the dosing tables [see Dosage and Administration ( 2.2 , 2.3 )]. Consider factors such as age, body weight, anticipated pathology and degree and extent of opacification required, structure(s) or area to be examined, concomitant medical conditions, and imaging equipment and technique to be employed. Hydrate patients prior to and following ISOVUE-M administration [see Warnings and Precautions ( 5.2) ] . Use aseptic technique for all handling and administration of ISOVUE-M. ISOVUE-M may be administered at either body temperature (37°C, 98.6°F) or room temperature (20°C to 25°C, 68°F to 77°F). Visually inspect ISOVUE-M for particulate matter and discoloration prior to administration whenever the solution and container permit. Do not administer ISOVUE-M if particulate matter or discoloration are observed. Do not mix ISOVUE-M with other drugs. ISOVUE-M is packaged in a single-dose vial and intended for one procedure only. Discard any unused portion.

US FDA label

Dosage forms

Philippines

  • Iodine) solution for injection for intravascular use only: 612.34 mg/mL (equivalent to 300 mg, 755.22 mg/mL (equivalent to 370 mg
  • Iodine) solution for injection: 612 mg/mL (equivalent to 300 mg, 612.34 mg/mL (equiv. to 300 mg, 612.34 mg/mL (equivalent to 300 mg, 612.4 mg/mL (Equivalent to 300 mg, 755 mg/mL (equivalent to 370 mg, 755.22 mg/mL (eq. to 370 mg
  • Iodine) solution for injection for intravascular use only n: 612.34 mg/mL (equivalent to 300 mg
  • Iodine) solution for intravascular injection: 612.40 mg/mL (equivalent to 300 mg
  • Of iodine) solution for injection: 612 mg/mL (equivalent to 300 mg/mL
  • Of iodine) sterile solution for injection: 755 mg/mL (370 mg/mL

Registered products in the Philippines

20 products registered with the Food and Drug Administration (FDA) Philippines list Iopamidol as the generic name (including products registered under a variant spelling). Registration status changes; confirm a product's current status on the FDA portal before relying on it.

Also registered under: Iopamidol l (1 product). Products registered under these spellings are included in the table and marked.

Verify on PH FDA portal

All registered products20
Philippine FDA-registered products for Iopamidol
Package insert
Btiray 300Iopamidol
612.40 mg/mL (equivalent to 300 mg iodine) Solution for Intravascular InjectionUSP type I clear colorless glass vial with grey bromobutyl rubber stopper and blue aluminum flip-off seal x 50 mL and 100 mL (Box of 1's)
Rx
İdol İlaç Dolum San. Ve Tic. A.Ş.Turkey
Exa Life Care Pharma Inc.Trader: Biem Pharmaceutical Co. A.S.
DRP-15700
Aug 29, 2029
DolmiraIopamidol
612.34 mg/mL (equivalent to 300mg Iodine) Solution for Injection for Intravascular Use only (Not for Intrathecal Use)Type I clear glass vial with 32mm gray bromobutyl rubber stopper and 32mm flip off aluminum seal with polypropylene disc x 50 mL (Box of 1's)
Rx
Jodas Expoim Pvt. Ltd.India
Medethix, Inc.Importer: I.E Medica Inc.
DRP-14405-01
Sep 5, 2028
IopamedIopamidol
612.34 mg/mL (equivalent to 300mg Iodine) Solution for Injection for Intravascular Use Only (Not for Intrathecal Use)Type I clear glass vial with 32 mm gray bromobutyl rubber stopper and 32 mm flip off aluminum seal with polypropylene disc x 50 mL (Box of 1's)
Rx
Jodas Expoim Pvt. Ltd.India
Medethix, Inc.Importer: I.E. Medica, Inc.
DRP-14405-02
Sep 5, 2028
IopamedixIopamidol
612.34 mg/mL (equivalent to 300 mg Iodine) Solution for Injection for Intravascular Use Only (Not for Intrathecal Use)Type I clear glass vial with 32 mm gray bromobutyl rubber stopper and 32 mm flip-off aluminum seal with polypropylene disc x 100 mL (Box of 1's)
Rx
Jodas Expoim Pvt. Ltd.India
Biopharma Medical Solution, Inc.Importer: I.E. Medica, Inc.
DRP-14406
Sep 5, 2028
IopamedixIopamidol
612.34 mg/mL (equivalent to 300 mg Iodine) Solution for Injection for Intravascular Use Only (Not for Intrathecal Use)nType I clear glass vial with 32 mm gray bromobutyl rubber stopper and 32 mm flip off aluminum seal with. polypropylene disc x 50 mL (Box of 1's)
Rx
Jodas Expoim Pvt. Ltd.India
I.E. Medica, Inc.
DRP-14404
Sep 5, 2028
IopamedixIopamidol
755.22 mg/mL (equivalent to 370 mg Iodine) Solution for Injection for Intravascular Use Only (Not for Intrathecal Use)Type I clear glass vial with 32 mm gray bromobutyl rubber stopper and 32 mm flip-off aluminum seal with polypropylene disc x 50 mL (Box of 1's)
Rx
Jodas Expoim Pvt. LtdIndia
Biopharma Medical Solution, Inc.Importer: I.E. Medica, Inc.
DRP-14408
Sep 5, 2028
IopamedixIopamidol
755.22 mg/mL (equivalent to 370 mg Iodine) Solution for Injection for Intravascular Use Only (Not for Intrathecal Use)Type I clear glass vial with 32 mm gray bromobutyl rubber stopper and 32 mm flip off aluminum seal with. FDA polypropylene disc x 100 mL (Box of 1's)
Rx
Jodas Expoim Pvt. Ltd.India
I.E. Medica, Inc.
DRP-14410
Sep 5, 2028
IopamiGetIopamidol
612.34 mg/mL (equivalent to 300 mg Iodine) Solution For InjectionGlass infusion bottle with rubber stopper and alu-plastic cap x 100 mL (Box of 30's and 60's)
Rx
Beta Drugs LimitedIndia
2MG Incorporated
DRP-18530
Jul 29, 2031
IopamiroIopamidol
612 mg/mL (equivalent to 300 mg Iodine) Solution for Injection (IV)Clear, colorless Type I glass vial with rubber stopper and blue flip-off seal (50 mL and 100 mL) (Box of 1's)
Rx
Patheon Italia S.P.AItaly
Metro Drug, Inc.Importer: New Marketlink Pharmaceutical Corporation
DR-XY34457
Apr 9, 2028
IopamiroIopamidol
755 mg/mL (equivalent to 370 mg Iodine) Solution for Injection (IA/IV)Type I colorless glass vial with blue flip-top seal and rubber stopper, 50 mL, 100 mL and 200 mL (Box of 1's)
Rx
Patheon Italia S.p.A.Italy
Metro Drug Inc.Importer: New Marketlink Pharmaceutical CorporationTrader: Brasco S.p.A.
DR-XY34136
Jan 8, 2028
Pamidol 300Iopamidol
612.4 mg/mL (Equivalent to 300 mg Iodine) Solution for Injection50 and 100 mL USP Type I Clear Glass Vial with Bromo Butyl Rubber Stopper and Blue Flip-off Seal [Box of 1's]
Rx
Unique Pharmaceutical Laboratories (A Division of J.B. Chemicals & Pharmaceuticals Ltd.)India
S.M.H.P. Marketing & ConsultancyTrader: J.B. Chemicals & Pharmaceuticals Limited
DRP-15188
May 22, 2029
PamisolIopamidol
612 mg/mL (equivalent to 300 mg Iodine) Solution for Injection (IV)USP Type I Clear glass vial x 50 mL and 100 mL with Rubber Stopper and Blue Flip-off Seal (Box of 1's)
Rx
Dongkook Pharmaceutical Co., Ltd.Republic of Korea
Endure Medical, Inc.
DRP-1160
Nov 10, 2027
ScanluxIopamidol
612 mg/mL (equivalent to 300 mg/mL of Iodine) Solution for Injection (Intravenous/Intra-arterial)Eur. Ph. Type II Clear Glass Vial x 50 mL and 100 mL with Rubber Stopper and Green Flip-off Seal (Box of 1's)
Rx
Sanochemia Pharmazeutika GMBHAustria
Sankem Healthcare Inc.
DR-XY34163
Jan 22, 2028
ScanluxIopamidol
755 mg/mL (370 mg/mL of Iodine) Sterile Solution for Injection (I.V. or Intraarterial)Eur. Ph. Type II clear glass vial with rubber stopper and orange flip-off seal in 50 mL and 100 mL (Box of 1's)
Rx
Sanochemia Pharmazeutika GmbHAustria
Sankem Healthcare Inc.
DR-XY34162
Jan 22, 2028
Stardol-300Iopamidol
612.34 mg/mL (equiv. to 300 mg Iodine) Solution For Injection (IV/IA)100 mL and 50 mL capacity USP Type I clear, colorless glass vial with rubber stopper and sky blue-colored flip-off Seal (Box of 1's)
Rx
Arco Lifesciences (I) Pvt. Ltd.India
SRS Life Sciences Inc.Trader: SRS Pharmaceuticals Pvt. Ltd.
DR-XY44897
Sep 2, 2031
Stardol-370Iopamidol
755.22 mg/mL (eq. to 370 mg Iodine) Solution For Injection (IV/IA)100 mL and 50 mL capacity USP Type I clear, colorless glass vial with rubber stopper and aluminum seal (Box of 1's)
Rx
Arco Lifesciences (I) Pvt. Ltd.India
SRS Life Sciences Inc.Trader: SRS Pharmaceuticals Pvt. Ltd.
DR-XY46354
Sep 3, 2031
(no brand name)Iopamidol
612.34 mg/mL (equivalent to 300 mg Iodine) Solution for Injection for Intravascular Use Only (Not for Intrathecal Use)Type I clear glass vial with 32 mm gray bromobutyl rubber stopper and 32 mm flip off aluminum seal with. polypropylene disc x 50 mL (Box of 1's)
Rx
Jodas Expoim Pvt. Ltd.India
I.E. Medica, Inc.
DRP-14405
Sep 5, 2028
(no brand name)Iopamidol lVariant spelling
612.34 mg/mL (equivalent to 300 mg Iodine) Solution for Injection for Intravascular Use Only (Not for Intrathecal Use)ype I clear glass vial with 32 mm gray bromobutyl rubber stopper and 32 mm flip off aluminum seal with. er FA polypropylene disc x 100 mL (Box of 1's)
Rx
Jodas Expoim Pvt. Ltd.India
I.E. Medica, Inc.
DRP-14407
Sep 5, 2028
(no brand name)Iopamidol
755.22 mg/mL (equivalent to 370 mg Iodine) Solution for Injection for Intravascular Use Only (Not for Intrathecal Use)Type I clear glass vial with 32 mm gray bromobutyl rubber stopper and 32 mm flip off aluminum seal with FBA polypropylene disc x 50 mL (Box of 1's)
Rx
Jodas Expoim Pvt. Ltd.India
I.E. Medica, Inc.
DRP-14409
Sep 5, 2028
(no brand name)Iopamidol
755.22 mg/mL (equivalent to 370 mg Iodine) Solution for Injection for Intravascular Use Only (Not for Intrathecal Use)Type I clear glass vial with 32 mm gray bromobutyl rubber stopper and 32 mm flip off aluminum seal with polypropylene disc x 100 mL (Box of 1's)
Rx
Jodas Expoim Pvt. Ltd.India
I.E. Medica, Inc.
DRP-14411
Sep 5, 2028

Source: FDA Philippines product registration database. "Valid until" is the registration validity date listed by the FDA; a past date may mean a renewal is pending. Package insert links point to files published by the FDA.

United States (label)

Dosage forms and strengths (US label) US FDA label

3 DOSAGE FORMS AND STRENGTHS Injection: clear, colorless to pale yellow solution available in two concentrations of iodine: Concentration (mg of Iodine/mL) Package Size Package Type 200 10 mL Single-Dose Vial 300 15 mL Single-Dose Vial Injection: 200 mg Iodine/mL and 300 mg Iodine/mL in single-dose vials (3)

Warnings/Precautions

Warnings and precautions (US label) US FDA label
  • Hypersensitivity Reactions: Life-threatening or fatal reactions can occur. Always have emergency resuscitation equipment and trained personnel available. (5.1)
  • Acute Kidney Injury: Acute injury including renal failure can occur. Use the lowest dose and maintain adequate hydration to minimize risk. (5.2)
  • Cardiovascular Adverse Reactions: Hemodynamic disturbances including shock and cardiac arrest may occur during or after ISOVUE-M administration. (5.4)
  • Thyroid Dysfunction in Pediatric Patients 0 Years to 3 Years of Age: Individualize thyroid function monitoring based on risk factors such as prematurity. (5.6)
5.1 Hypersensitivity Reactions

5.1 Hypersensitivity Reactions ISOVUE-M can cause life-threatening or fatal hypersensitivity reactions including anaphylaxis. Manifestations include respiratory arrest, laryngospasm, bronchospasm, angioedema, and shock [see Adverse Reactions (6.2)]. Most severe reactions develop shortly after the start of injection (e.g., within 1 to 3 minutes), but delayed reactions can also occur.

There is increased risk of hypersensitivity reactions in patients with a history of previous reactions to contrast agents, and known allergic disorders (i.e., bronchial asthma, allergic rhinitis, and food allergies) or other hypersensitivities. Premedication with antihistamines or corticosteroids does not prevent serious life-threatening reactions, but may reduce their incidence and severity.

Obtain a history of allergy or hypersensitivity reactions to iodinated contrast agents and always have emergency resuscitation equipment and trained personnel available prior to ISOVUE-M administration. Monitor all patients for hypersensitivity reactions.

5.2 Acute Kidney Injury

5.2 Acute Kidney Injury Acute kidney injury, including renal failure, may occur after administration of iodinated contrast agents. Risk factors include pre-existing renal insufficiency, dehydration, diabetes mellitus, congestive heart failure, advanced vascular disease, elderly age, concomitant use of nephrotoxic or diuretic medications, multiple myeloma or other paraproteinemias, and repetitive or large doses of iodinated contrast agents.

Use the lowest dose of ISOVUE-M, especially in patients with risk factors for acute kidney injury. Adequately hydrate patients prior to and following ISOVUE-M administration.

5.3 Increased Risk of Seizures

5.3 Increased Risk of Seizures Focal and generalized motor seizures have been reported after intrathecal use of iodinated contrast agents including ISOVUE-M. In several of the cases, higher than recommended doses were administered. Use of medications that may lower the seizure threshold (phenothiazine derivatives, including those used for their antihistaminic properties; tricyclic antidepressants; MAO inhibitors; CNS stimulants; analeptics; antipsychotic agents) should be carefully evaluated.

Consider discontinuing these agents at least 48 hours before and for at least 24 hours following intrathecal administration of ISOVUE-M.

5.4 Cardiovascular Adverse Reactions

5.4 Cardiovascular Adverse Reactions Iodinated contrast agents increase the circulatory osmotic load and may induce acute or delayed hemodynamic disturbances in patients with congestive heart failure, severely impaired renal function, combined renal and hepatic disease, and combined renal and cardiac disease, particularly when repetitive or large doses are administered. Fatal cardiovascular reactions have occurred mostly within 10 minutes of injection of iodinated contrast agent by an intravascular route; the main feature was cardiac arrest with cardiovascular disease as the main underlying factor.

Hypotensive collapse and shock have occurred. The administration of iodinated contrast agent may cause pulmonary edema in patients with heart failure. Based upon published reports, deaths associated with the administration of iodinated contrast agents range from 6.6 per 1 million (0.00066 percent) to 1 in 10,000 patients (0.01 percent).

Use the lowest necessary dose of ISOVUE-M in patients with congestive heart failure and always have emergency resuscitation equipment and trained personnel available. Monitor all patients for severe cardiovascular reactions.

5.5 Thyroid Storm in Patients with Hyperthyroidism

5.5 Thyroid Storm in Patients with Hyperthyroidism Thyroid storm has occurred after the use of iodinated contrast agents in patients with hyperthyroidism, or with an autonomously functioning thyroid nodule. Evaluate the risk in such patients before use of ISOVUE-M.

5.6 Thyroid Dysfunction in Pediatric Patients 0 Years to 3 Years of Age

5.6 Thyroid Dysfunction in Pediatric Patients 0 Years to 3 Years of Age Thyroid dysfunction characterized by hypothyroidism or transient thyroid suppression has been reported after both single exposure and multiple exposures to iodinated contrast agents in pediatric patients 0 years to 3 years of age. Younger age, very low birth weight, prematurity, underlying medical conditions affecting thyroid function, admission to neonatal or pediatric intensive care units, and congenital cardiac conditions are associated with an increased risk of hypothyroidism after iodinated contrast agent exposure.

Pediatric patients with congenital cardiac conditions may be at greatest risk given that they often require high doses of contrast during invasive cardiac procedures. An underactive thyroid during early life may be harmful for cognitive and neurological development and may require thyroid hormone replacement therapy. After exposure to iodinated contrast agent, individualize thyroid function monitoring based on underlying risk factors, especially in term and preterm neonates.

ISOVUE-M is not indicated for use in pediatric patients younger than 2 years of age [see Use in Specific Populations (8.4)].

5.7 Hypertensive Crisis in Patients with Pheochromocytoma

5.7 Hypertensive Crisis in Patients with Pheochromocytoma Hypertensive crisis in patients with pheochromocytoma has occurred with iodinated contrast agents. Closely monitor patients when administering ISOVUE-M if pheochromocytoma or catecholamine-secreting paragangliomas are suspected. Inject the minimum amount of ISOVUE-M necessary and have measures for treatment of hypertensive crisis readily available.

5.8 Sickle Cell Crisis in Patients

5.8 Sickle Cell Crisis in Patients with Sickle Cell Disease Iodinated contrast agents may promote sickling in individuals who are homozygous for sickle cell disease. Hydrate patients prior to and following ISOVUE-M administration and use only if the necessary imaging information cannot be obtained with alternative imaging modalities.

5.9 Severe Cutaneous Adverse Reactions

5.9 Severe Cutaneous Adverse Reactions Severe cutaneous adverse reactions (SCAR) may develop from 1 hour to several weeks after administration of iodinated contrast agent. These reactions include Stevens-Johnson syndrome and toxic epidermal necrolysis (SJS/TEN), acute generalized exanthematous pustulosis (AGEP), and drug reaction with eosinophilia and systemic symptoms (DRESS).

Reaction severity may increase and time to onset may decrease with repeat administration of contrast agent; prophylactic medications may not prevent or mitigate severe cutaneous adverse reactions. Avoid administering ISOVUE-M to patients with a history of a severe cutaneous adverse reaction to ISOVUE-M.

5.10 Interference with Laboratory Test

5.10 Interference with Laboratory Test ISOVUE-M can interfere with protein-bound iodine test [see Drug Interactions (7.2)].

Adverse reactions

Adverse reactions (US label) US FDA label
  • The following adverse reactions are described in greater detail in other sections: Hypersensitivity Reactions [see Warnings and Precautions (5.1)] Acute Kidney Injury [see Warnings and Precautions (5.2)] Increased Risk of Seizures [see Warnings and Precautions (5.3)] Cardiovascular Adverse Reactions [see Warnings and Precautions (5.4)] Thyroid Dysfunction in Pediatric Patients 0 to 3 Years of Age [see Warnings and Precautions (5.6)] Severe Cutaneous Adverse Reactions [see Warnings and Precautions (5.9)] Most common adverse reactions (incidence > 1%) are headache, nausea, vomiting, back pain, leg pain, neck pain, and hypotension. (6.1)
  • To report SUSPECTED ADVERSE REACTIONS, contact Bracco Diagnostics Inc. at 1-800-257-5181 or FDA at 1-800-FDA-1088 or www.fda.gov/medwatch.
6.1 Clinical Trials Experience

6.1 Clinical Trials Experience Because clinical trials are conducted under widely varying conditions, adverse reaction rates observed in the clinical trials of a drug cannot be directly compared to rates in the clinical trials of another drug and may not reflect the rates observed in practice. The safety of ISOVUE-M was evaluated in 686 adult patients receiving ISOVUE-M intrathecally in clinical studies.

Table 3 shows the common adverse reactions (>1%). These reactions usually occur 1 to 10 hours after injection, almost all occurring within 24 hours. Table 3: Adverse Reactions Reported in >1% of Patients Receiving Intrathecal Injection of ISOVUE-M in Clinical Studies Adverse Reaction ISOVUE-M (N=686) % Headache 16.4 Nausea 7.3 Vomiting 3.6 Back pain 2.2 Leg Pain 1.4 Neck Pain 1.1 Hypotension 1.1 The following additional adverse reactions occurred in ≤ 1% of patients receiving intrathecal injection of ISOVUE-M: Cardiovascular disorder: tachycardia, hypertension, chest pain Gastrointestinal: diarrhea, heartburn General disorders and administration site conditions: pyrexia, muscle weakness, hot flashes, malaise, fatigue, weakness, injection site pain Musculoskeletal: leg cramps, sciatica, cervicobrachial irritation, meningeal irritation, radicular irritation lumbosacral, other musculoskeletal pain, involuntary movement, burning sensation Nervous system: dizziness, paresthesia, confusion, hallucinations, lightheadedness, syncope, numbness, cold extremities, ataxia, irritability Urogenital: urinary retention Respiratory: dyspnea Skin and subcutaneous tissues: rash

6.2 Postmarketing Experience

6.2 Postmarketing Experience The following adverse reactions have been identified during postapproval use of ISOVUE-M and other iopamidol products. Because the reactions are reported voluntarily from a population of uncertain size, it is not always possible to reliably estimate their frequency or to establish a causal relationship to drug exposure.

Blood and lymphatic system disorders: thrombocytopenia Cardiovascular disorders: cardiopulmonary arrest, cardiac decompensation, arrhythmias, myocardial infarction, shock, electrocardiographic changes (e.g., increased QTc, increased R-R, increased T-wave amplitude), decreased systolic pressure, deep vein thrombosis, arterial spasms, transient ischemic attack, flushing, vasodilation, chest pain, pallor Endocrine disorders: hyperthyroidism, hypothyroidism Eye disorders: lacrimation increased, conjunctivitis, eye pruritus, transient blindness, visual disturbance, photophobia Gastrointestinal disorders: retching, abdominal pain, salivary hypersecretion, salivary gland enlargement General disorders and administration site conditions: chills, malaise Immune system disorders: anaphylaxis characterized by cardiovascular, respiratory, and cutaneous manifestations (e.g., chest tightness, laryngeal edema, periorbital edema, facial edema); delayed hypersensitivity reactions including generalized maculopapular rash, erythema, pruritus, localized blistering, skin peeling Infections and infestations: meningitis aseptic, meningitis bacterial as consequence of the procedural hazard Musculoskeletal disorders: muscle spasm, musculoskeletal pain, muscular weakness Nervous system: coma, seizure, tremors, syncope, cerebral edema, paralysis, depressed level of consciousness or loss of consciousness, meningism, encephalopathy Psychiatric disorders: disorientation, agitation, restlessness, confusional state Respiratory system disorders: respiratory arrest, respiratory failure, acute respiratory distress syndrome, respiratory distress, apnea, asthma, sneezing, choking, laryngeal edema, bronchospasm, rhinitis Skin and subcutaneous tissue disorders: Stevens-Johnson syndrome and toxic epidermal necrolysis (SJS/TEN), acute generalized exanthematous pustulosis (AGEP), erythema multiforme and drug reaction with eosinophilia and systemic symptoms (DRESS), skin necrosis, face edema

Adverse reaction frequency tables (US label) US FDA label
Table 3: Adverse Reactions Reported in >1% of Patients Receiving Intrathecal Injection of ISOVUE-M in Clinical Studies
Adverse ReactionISOVUE-M (N=686) %
Headache16.4
Nausea7.3
Vomiting3.6
Back pain2.2
Leg Pain1.4
Neck Pain1.1
Hypotension1.1

Pharmacokinetics

Half-life and elimination (verbatim, US label)

Elimination The plasma half-life is approximately 2 hours; the half-life is not dose dependent .

Excretion Iopamidol is excreted mainly through the kidneys following intrathecal administration, and the drug is essentially undetectable in the plasma 48 hours later.

In patients with normal renal function, the cumulative urinary excretion for iopamidol, expressed as a percentage of administered intravenous dose is approximately 35% to 40% at 60 minutes, 80% to 90% at 8 hours, and 90% or more in the 72- to 96-hour period after administration.

Pharmacokinetics (US label) US FDA label

12 CLINICAL PHARMACOLOGY 12.1 Mechanism of Action Intrathecal administration of iopamidol opacifies the body structures where the contrast agent is present, permitting their radiographic visualization through attenuation of photons. 12.2 Pharmacodynamics Following intrathecal injection, iopamidol provides diagnostic contrast for at least 30 minutes for conventional myelography. At about 1 hour, contrast will no longer be sufficient for conventional myelography.

However, diagnostic contrast for CT myelography remains at least 6 hours after administration. The exposure-response relationships and time course of pharmacodynamic response of iopamidol have not been fully characterized. 12.3 Pharmacokinetics Absorption Iopamidol is absorbed into the bloodstream from cerebrospinal fluid (CSF); following intrathecal administration, iopamidol appears in plasma within 1 hour and virtually all of the drug reaches the systemic circulation within 24 hours.

Distribution Iopamidol did not bind to serum or plasma proteins at 1 hour after administration. Elimination The plasma half-life is approximately 2 hours; the half-life is not dose dependent. Metabolism Iopamidol does not undergo significant metabolism, deiodination, or biotransformation. Excretion Iopamidol is excreted mainly through the kidneys following intrathecal administration, and the drug is essentially undetectable in the plasma 48 hours later.

In patients with normal renal function, the cumulative urinary excretion for iopamidol, expressed as a percentage of administered intravenous dose is approximately 35% to 40% at 60 minutes, 80% to 90% at 8 hours, and 90% or more in the 72- to 96-hour period after administration. In patients with normal renal function, approximately 1% or less of the administered dose appears in cumulative 72- to 96-hour fecal specimens.

Formulary and pricing (Philippines)

Government price references

PreparationPrice (PHP)UnitType
Iopamidol 612 mg/mL equiv. to 300 mg iodine, 100 mL Vial₱1,306.80–₱1,448.80Reference ₱1,306.80per vialDPRI procurement range
Iopamidol 612 mg/mL equiv. to 300 mg iodine, 50 mL Vial₱588.88–₱788.88Reference ₱712.80per vialDPRI procurement range
Iopamidol 755 mg/mL equiv. to 370 mg iodine, 100 mL Vial₱1,450.80–₱1,887.90Reference ₱1,450.80per vialDPRI procurement range
Iopamidol 755 mg/mL equiv. to 370 mg iodine, 50 mL Vial₱708.00–₱1,300.00Reference ₱1,002.50per vialDPRI procurement range

Range = lowest-highest procurement price (highest usable only in GIDA areas); reference_price = 2021 DPRI ceiling (median)

These are government procurement and reimbursement references, not retail prices. Sources:

Formulary and coverage

Philippine National FormularyListed as Iopamidol
PNF listingInj.: (Intravascular and other parenteral routes as appropriate)
PNF listingInj.: 612 mg/mL equiv. to 300 mg iodine, 50 mL and 100 mL vial
PNF listingInj.: 755 mg/mL equiv. to 370 mg iodine, 50 mL and 100 mL vial/bottle
PhilHealth GAMOTNo

Sources:

Check availability

Prices and stock vary by branch; renalcarematters.com does not sell medicines or receive payment from pharmacies.

References

  1. U.S. Food and Drug Administration. ISOVUE-M · Bracco Diagnostics Inc [US FDA-approved label, version 10, February 10, 2026]. Via DailyMed/openFDA. https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=11e893d2-0183-4581-b908-c8b7302c7edb
  2. Food and Drug Administration Philippines. Verification portal (product registrations). https://verification.fda.gov.ph
  3. PNF Essential Medicines List, 8th ed. (as of November 2, 2022), DOH; https://www.philhealth.gov.ph/partners/providers/pdf/PNF-EML_11022022.pdf
  4. DOH Drug Price Reference Index (DPRI) 2021, 9th edition (as of September 17, 2021); https://caro.doh.gov.ph/wp-content/uploads/2021/09/2021DPRI-as-of-9-17-2021.pdf

This page shows official label and registry text only; no renalcarematters.com clinical summary has been approved for it yet.

For health professionals. This page is a reference compiled from public regulatory sources for licensed health professionals in the Philippines. Verify every product detail against the current Philippine package insert and the FDA Philippines registration record. Information here is not a substitute for clinical judgment and does not replace the prescribing information approved for the specific product you dispense or prescribe.

Last updated: .